{"entity":{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","aka":[],"tldr":"A phase 1/2 trial of EP0031 and Pemetrexed in non-small-cell lung cancer, run by Ellipses Pharma, now recruiting.","summary":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies is a phase 1/2 interventional study registered as NCT05443126 by Ellipses Pharma, with 265 participants planned, started 2022-09-30 and due to reach its primary completion in 2027-03. Interventions recorded: EP0031, Platinum chemotherapy and Pemetrexed.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05443126","url":"https://clinicaltrials.gov/study/NCT05443126"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","ret-fusion-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ep0031","pemetrexed"],"companies":["ellipses-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05443126","phase":"1/2","setting":"A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies","sponsor":"Ellipses Pharma","participation":[{"nct":"NCT05443126","source":"https://clinicaltrials.gov/study/NCT05443126","fetchedAt":"2026-10-07T16:53:42.604Z","studySha256":"da8223a4f17f3061a07a3c5082ddfc728d62deaa554d40a305b56cb3cde6c866","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-01","leadSponsor":"Ellipses Pharma","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":265,"enrolmentType":"ESTIMATED","siteCount":52,"recruitingSiteCount":42,"countries":["France","Germany","Italy","Poland","Spain","United Arab Emirates","United Kingdom","United States"]}],"started":"2022-09-30","startedType":"actual","enrolled":265,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05443126/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"}],"drug":[{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/"}]}}